Trends in Angiotensin II Receptor Blocker (ARB) prescribing among general practitioners in the UK

Nov-06

AUTHORS : Betina Blak (Details for study: University of Maryland) now works at AstraZeneca, Horizon Place, 600 Capability Green, Luton, Bedfordshire LU1 3LU, UK – Email: betina.blak@astrazeneca.com

JOURNAL : Value in Health

REFERENCE: 9(6):A204

DOI : 10.1016/S1098-3015(10)63208-1

Trends in Angiotensin II Receptor Blocker (ARB) prescribing among general practitioners in the UK

More publications

Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes

Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study

Increased risk of fracture among patients with iron overload: a population-based matched cohort study